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Removal of P-Cresol Sulfate by Hemodialysis 
Andres W. Martinez, Natalie S. Recht, Thomas H. Hostetter, and Timothy W. Meyer 
Protein-bound solutes are poorly cleared by dialysis. Among the most extensively studied of these 
solutes is p-cresol, which has been shown to be toxic in vitro. This study examined the form in 
which p-cresol circulates and quantified its removal by hemodialysis. HPLC analysis of plasma 
from hemodialysis patients contained a peak whose mobility corresponded to synthetic p-cresol 
sulfate (PCS) but no detectable unconjugated p-cresol. Treatment with sulfatase resulted in 
recovery of this peak as p-cresol, confirming its identity. Subsequent studies compared the 
removal of PCS and another protein-bound solute, indican, to the removal of urea during clinical 
hemodialysis treatments. PCS and indican were 94 ± 1% and 93 ± 2% bound to plasma protein, 
respectively. Protein-binding caused a predictable decrease in measured dialytic clearance, which 
averaged 20 ± 4 ml/min for PCS and 25 ± 5 ml/min for indican as compared with 260 ± 20 ml/min 
for urea. Volumes of distribution for the protein-bound solutes were greater than the plasma 
volume, averaging 15 ± 7 L for PCS and 14 ± 3 L for indican as compared with 37 ± 7 for urea. 
Solute reduction ratios were 20 ± 9% for PCS, 30 ± 7% for indican, and 69 ± 5% for urea. We
conclude that p-cresol circulates in the form of its sulfate conjugate, PCS. PCS is poorly removed 
by hemodialysis because its clearance is limited by protein binding and the ratio of its volume of 
distribution to its clearance is high. 
The adequacy of hemodialysis is now assessed by measuring urea removal. But this practice is not 
based on evidence that urea causes uremic toxicity (1–3). It is widely recognized, moreover, that the 
behavior of urea during dialysis is not representative of the behavior of all uremic solutes (4). One class 
of solutes which do not behave like urea are those that bind to plasma proteins, particularly albumin 
(5,6). The normal kidney can clear such solutes by tubular secretion, but protein binding impairs their 
clearance during hemodialysis such that plasma levels in dialysis patients, when expressed as multiples 
of normal, often exceed levels of urea (4). Accumulation of such solutes could contribute to residual 
uremic toxicity when urea removal is adequate. 
Among the most extensively studied of protein-bound solutes has been p-cresol. This compound is
one of a large number of phenols derived from degradation of the amino acid phenylalanine and from 
phenol compounds in vegetable foods. Many phenols accumulate in uremia and there has been 
longstanding interest in their contribution to uremic toxicity (7–10). Interest has focused on p-cresol 
because its plasma levels are higher than those of most uremic solutes and because in vitro studies have 
shown that it has toxic effects (11–14). Recent studies have confirmed that protein binding limits the 
removal of p-cresol by dialysis and associated high p-cresol levels with poor outcomes in dialysis 
patients (15–17). 
The goal of our study was to better understand the removal of p-cresol by hemodialysis. An initial, 
and unexpected, finding was that p-cresol is present in plasma largely in the form of its sulfate 
conjugate, p-cresol sulfate (PCS). We found that PCS, like p-cresol, binds avidly to plasma proteins. Our 
 
 
 
 
 
 
results suggest that acid hydrolysis of PCS during deproteination of plasma samples has led to the 
reporting of high plasma p-cresol levels in previous studies of uremic patients. We therefore proceeded 
to measure the removal of PCS and another protein-bound solute, indican, by hemodialysis. The 
clearances of PCS and indican were much lower than the clearance of urea. We found further that the 
volumes of distribution for PCS and indican greatly exceed the plasma volume. Conventional he­
modialysis is ineffective in reducing the plasma levels of these solutes because their volumes of 
distribution are large relative to their dialytic clearance rates.
Materials and Methods 
Analytic Methods 
PCS and indican in plasma and dialysate were assayed by HPLC using an Agilent 1100 Series 
system (Agilent, Palo Alto, CA). Plasma samples were deproteinized by the addition of 3 parts methanol 
to 1 part plasma. The free concentration was measured in plasma ultrafiltrates obtained using Microcon 
YM-30 separators (Millipore, Billerica, MA). Because concentrations of indican and PCS in dialysate 
are low, dialysate was concentrated eight-fold by rotary evaporation before assay by HPLC. 
To develop a PCS assay, PCS was synthesized as described by Feigenbaum and Neuberg (18) and 
purified by recrystallization from ethanol. In this procedure, p-cresol dissolved in pyridine is converted 
to PCS by the slow addition of chlorosulfonic acid. PCS is crystallized out of the reaction mixture by 
addition of ethanol and then purified by recrystallization from 90% ethanol, 10% water. The identity of 
the synthetic compound was confirmed by electrospray ionization mass spectrometry (ESI-MS) as 
illustrated in Figure 1. Fluorescence spectra of synthetic PCS were then examined using a luminescence 
spectrometer (LS50B, Perkin-Elmer, Wellesley, MA). An HPLC assay using detection at the optimum
fluorescence values of excitation (214 nm) and emission (306 nm) was performed at room temperature 
on a reverse phase C18 column of 4.6 mm X 15 cm. Buffer flow was 1 ml/min using methanol (A) and 
ammonium formate (50 mM, pH 4) (B) with a gradient from 35%A/65%B to 75%A/25%B over 15 min. 
Under these conditions, PCS appeared at 5.2 min and standard curves from aqueous synthetic PCS at 1, 
2, 4, and 8 mg/dl processed like plasma samples had average r2 values of 0.9998 ± 0.0001. Recovery of 
PCS with the assay was 100 ± 1% of PCS added to normal plasma to achieve concentrations similar to 
those found in patients on dialysis (n = 4) and 100 ± 6% of PCS (n = 4) added to fresh dialysate to 
achieve concentrations similar to those found in spent dialysate. Repeat PCS assay of plasma from 
dialysis patients in the same HPLC assay yielded 94 ± 7% of the original value (n = 6) and repeat assay 
on plasma stored frozen at —80°C for 4 to 7 wk yielded 95 ± 11% of the original value (n = 6). Values 
for PCS concentration are given in mg/dl of PCS (mol wt, 188 daltons). P-cresol in the same assay 
appeared at 9.9 min. The sensitivity of this assay for p-cresol, as determined by adding reagent p-cresol 
to samples of plasma from normal subjects, was <0.01 mg/dl, with recovery of 101 ± 7% at 0.0125 
mg/dl (n = 3). 
Indican was measured with fluorescence detection using a protocol based on those of Niwa et al.
(19) and Fagugli et al. (15), using excitation 295 nm and emission 390 nm. Buffer flow was 1 ml/min 
employing methanol (A) and ammonium formate (50 mM, pH 4) (B) with a gradient from 15%A/85%B 
to 80%A/20%B over 25 min. Under these conditions, indican appeared at 8.4 min and standard curves 
  
 
 
 
 
 
from aqueous reagent indican at 0.25, 0.5, and 1.0 mg/dl and had average r2 values of 0.99999 ± 
0.00001. Recovery with the assay was 100 ± 1% of indican added to normal plasma to achieve 
concentrations similar to those found in patients on dialysis (n = 4) and 100 ± 6% of indican (n = 4) 
added to fresh dialysate to achieve concentrations similar to those found in spent dialysate. Repeat assay 
of plasma from dialysis patients in the same HPLC assay yielded 99 ± 1% of the original value (n = 6) 
and repeat assay on plasma stored frozen at —80°C for 4 to 7 wk yielded 97 ± 10% of the original value 
(n = 6). 
Methanol deproteinization was used as described above to avoid hydrolysis of PCS by acid. 
Additional samples were reassayed to assess the extent to which previously described acid precipitation 
methods convert PCS to p-cresol. Five predialysis samples were treated with HCl as described by De
Smet et al. (20). To 150 µl of sample, 22.5 µl of 6N HCl was added, after which 150 mg of NaCl was 
added. Four predialysis samples were treated with H2SO4 as described by Bammens et al. (21). Two 
hundred microliters of serum were diluted with 180 µl of water and the pH was lowered to 1.0 by the 
addition of concentrated H2SO4, after which the mixture was heated to 90°C for 1 h. P-cresol was 
measured after ethylacetate extraction (1:1) of the acidified plasma mixtures and of the same predialysis 
plasma samples. The sensitivity of the plasma assay for p-cresol using ethyl acetate extraction, as deter­
mined by adding p-cresol to normal plasma, was <0.01 mg/dl plasma, with recovery of 113 ± 4% for 
0.0125 mg/dl (n = 3). 
Urea was measured using a commercial kit (#1770–50, ThermoDMA, Arlington, TX). Reagents 
including bovine P-glucuronidase type B-10, and sulfatase type H-1 powder from Helix pomatia
(#S9626–10KU) were obtained from Sigma (St. Louis, MO). 
Clinical Studies
Indican and PCS clearances were measured during the third session of the week in five stable 
outpatients (4 male/1 female) receiving hemodialysis three times weekly using Fresenius F70NR 
kidneys, which are not reused and have a surface area of 1.6 m2 provided by polysulfone fibers. Solute 
levels were measured in plasma samples obtained pre- and postdialysis and in dialysate collected during 
the treatment (average 178 ± 12 L). The average ultrafiltration rate was 21 ± 6 ml/min. The immediate 
postdialysis blood sample was collected after reducing the arterial flow to 100 ml/min for 10 s. The 
arterial access was then left in place and an additional blood sample was obtained at 30 min postdialysis 
to assess rebound of solute concentrations. Urea levels were measured in simultaneous arterial and 
venous samples obtained at 30, 90, and 150 min for measurement of urea clearance. To determine values 
for the solute free fraction f, solute levels were measured in Microcon 30 ultrafiltrates of the plasma
samples obtained pre- and postdialysis. The mean of these values was used in modeling the clearances of 
the protein-bound solutes. The volume of distribution for urea was calculated from the pre- and 
postplasma solute levels, the dialysate solute content, and the ultrafiltration rate using a single 
compartment variable-volume model (22). For the protein-bound solutes, however, a constant volume
was assumed because the effect of ultrafiltration on volume of distribution cannot be predicted. 
Clearance values for urea, expressed in ml/min of plasma, were calculated from urea concentrations
measured in the three simultaneous arterial and venous samples and from values for blood flow and 
  
 
 
 
 
 
 
hematocrit using standard formulas. Clearance values for PCS and indican cannot be obtained from 
simultaneous arterial and venous concentrations because the concentration differences across the kidney 
are too small. Clearance values for these solutes were therefore obtained from solute removal as 
measured in the total dialysate collection and pre- and postdialysis plasma levels. Separate experiments 
were performed to confirm that the solute concentrations in Microcon 30 ultrafiltrates accurately 
represented the free concentration of solute available for diffusion across the kidney membrane. Three 
patients were shifted to ultrafiltration mode after 150 min and ultrafiltered at the rate of 1000 ml/h for 30 
min. Samples of plasma and ultrafiltrate were then collected for determination of the solute free 
fractions. Solute free fractions obtained using ultrafiltrate obtained during dialysis (indican, 7 ± 3%; 
PCS, 8 ± 4%) were very close to those measured simultaneously using a Microcon 30 (indican, 7 ± 2%; 
PCS 6 ± 3%). Additional measurements showed that the Microcon filters did not absorb PCS (recovery 
in filtrate 99 ± 1%).
The clearance values calculated from blood and dialysate solute content were compared with those 
predicted by a recently described model for the dialysis of protein-bound solutes (23,24). Input values 
for the model include the blood flow Qb, the dialysate flow Qd, the ultra-filtration rate Qf, hematocrit, 
the free solute fraction f, and the dialyzer mass transfer area coefficient KoA for the solute of interest.
KoA values for indican and urea were measured in separate in vitro clearance experiments (n = 6). In 
these experiments, the solutes were dissolved in a buffered saline solution and dialyzed out of a 4-L
reservoir using the F70NR dialyzer with reservoir fluid flow 400 ml/min and dialysate flow of 800 
ml/min. Values for KoA of 665 ml/min for indican and 731 ml/min for urea were obtained from
measured solute clearance values using the equation derived by Michaels (25). The KoA for PCS (mw 
187) was assumed to be the same as that for indican (mol wt 213 daltons). 
Samples were obtained from a larger group of chronic hemodialysis patients to assess the relative 
plasma concentrations of p-cresol and PCS. Samples were obtained immediately before the third 
treatment of the week in 19 patients who had been on dialysis for an average of 3.7 ± 3.6 yr. Plasma
levels and 24-h urinary excretion rates for PCS and indican were measured in four normal adult subjects 
(1 female/3 male) for comparison with the values obtained in dialysis patients. 
Values are expressed as the mean ± SD throughout. 
Results 
Initial studies assessed the relative abundance of p-cresol and PCS in the plasma of patients with 
ESRD. Assay using the PCS protocol described in the methods revealed an average PCS level of 3.9 ± 
1.5 mg/dl and no detectable p-cresol. 
To confirm that the compound measured in predialysis samples was PCS, samples from five patients 
were assayed before and after incubation for 24 h at 37°C with sulfatase type H-1 powder from Helix 
pomatia as described by Niwa et al. (8). Assay before sulfatase treatment revealed an average PCS con­
centration of 4.2 ± 1.0 mg/dl and no detectable p-cresol. After sulfatase treatment, the original PCS peak 
was no longer present, and a new p-cresol peak appeared, which corresponded to a recovery of 95 ± 
13% of the original PCS peak as p-cresol (Figure 2).
To allow comparison of our results with those of other studies, additional samples were reassayed 
  
 
 
 
 
 
using previously reported methods in which acid treatment has been used to free bound solutes from 
plasma proteins. Five predialysis samples in which the mean PCS level was 4.2 ± 1.0 mg/dl were 
deproteinized with 6N HCl as described by De Smet et al. (20). We found that acid treatment in this 
manner yielded a recovery of 44 ± 12% of the original PCS peak as p-cresol. Ethyl acetate extracts 
(ethyl acetate:plasma 2:1) of the same predialysis samples yielded no detectable p-cresol. In four 
additional predialysis samples, the pH was lowered to 1.0 by the addition of concentrated H2SO4 using 
the alternate procedure of Bammens et al. (21). Acid treatment in this manner yielded a recovery of 73 ± 
4% of the original PCS peak as p-cresol, while again no p-cresol was detected by ethyl acetate extraction 
in the same samples. 
The results described above indicated that p-cresol is present in the plasma of dialysis patients 
largely in the form of PCS. Further studies, therefore, assessed the dialytic removal of PCS. Clinical 
parameters of the patients studied are summarized in Table 1. Blood flow during the runs averaged 379 
± 21 ml/min as recorded by the machine. Measured dialysate flow was 804 ± 15 ml/min with the 
nominal dialysate flow set at 800 ml/min. 
Results of clearance studies are summarized in Table 2. As expected, urea was removed effectively 
by hemodialysis. The predialysis concentration of 57 ± 10 mg/dl fell to 18 ± 4 mg/dl for a solute
reduction ratio of 0.69 ± 0.05. Urea nitrogen removed as measured in the dialysate was 18.0 ± 2.1 x 103 
mg, and the postdialysis urea volume of distribution calculated using a single compartment variable 
volume model was 37 ± 7 L. The urea clearance calculated using this model was 251 ± 33 ml/min while 
the urea clearance calculated from arterial-venous concentration differences measured across the kidney 
three times during each run was 260 ± 20 ml/min. These measured values were slightly lower than the 
clearance value of 303 ± 11 ml/min predicted from values for Qb, Qd, Qf, hematocrit, and KoA. 
Results for the protein-bound solutes PCS and indican were quite different from those for urea. The 
free fractions for both solutes declined during the course of dialysis, with the free faction of PCS falling 
from 7.8 ± 1.3% at the beginning of treatment to 4.7 ± 1.4% at the end of treatment, and the free fraction 
of indican falling from 7.6 ± 1.5% to 5.4 ± 2.2%. Protein binding limited solute removal so that the 
solute reduction ratios for PCS and indican were only 0.27 ± 0.11 and 0.30 ± 0.07. Solute removal 
measured in the dialysate was 161 ± 62 mg for PCS and 119 ± 59 mg for indican. Volumes of 
distribution calculated from solute removal and plasma concentrations were similar for the two protein 
bound solutes, averaging 15 ± 7 L for PCS and 14 ± 3 L for indican. Calculated clearance values for the 
protein-bound solutes were on the order of one tenth of the clearance value for urea, averaging 20 ± 4 
ml/min and 25 ± 5 ml/min, respectively. These clearance values, which were calculated from the 
measured solute removal and plasma concentrations, were again slightly lower than those predicted from
values for f, KoA, Qb, Qd, Qf, and hematocrit (23,24). 
Low clearance rates for the protein-bound solutes reflected limited removal of these solutes during 
passage of blood through the artificial kidney. Because removal of these solutes was limited, arterial-
venous concentration differences were hard to detect. Moreover, ultrafiltration raises the plasma protein 
concentration as blood passes through the kidney. This tends to increase the concentration of protein-
bound solutes in venous blood samples and conceal their removal by dialysis. In our study, in which the 
ultrafiltration rate averaged 9 ± 2% of the plasma flow rate, the arterial-venous concentration differences 
  
 
 
 
 
 
 
averaged only —1 ± 1% for PCS and —2 ± 2% for indican as compared with —75 ± 3% for urea. 
Measurements were made postdialysis to assess possible rebound of solute levels. The urea nitrogen 
rose from 18 ± 4 mg/dl at the end of treatment to 22 ± 5 mg/dl at 30 min posttreatment. The levels of 
PCS and indican, however, did not change significantly. The plasma albumin declined from 4.8 ± 0.7 at 
the end of dialysis to 4.6 ± 0.6 g/dl at 30 min postdialysis. Based on the assumption that this decline was 
caused by refilling of the vascular compartment, there was negligible movement of the protein-bound 
solutes into the plasma over 30 min postdialysis, with the calculated solute flux being only 2 ± 4 mg for 
PCS and 2 ± 2 mg for indican. 
Plasma levels of PCS and indican were much lower in four normal subjects than in the dialysis 
patients, averaging 0.38 ± 0.33 mg/dl and 0.10 ± 0.04 mg/dl, respectively. Twenty-four– hour urine 
excretion in the normal subjects averaged 78 ± 34 mg for PCS and 69 ± 23 mg for indican. 
Discussion
The first finding of this study was that p-cresol is present in the plasma in the form of PCS. We
found, in the course of developing our assays, that the reagent p-cresol could be quantitatively recovered 
from normal plasma by extraction with the organic solvent ethyl acetate. But no p-cresol was found in 
ethyl acetate extracts of uremic plasma. Deproteination of uremic plasma with methanol, however, 
yielded a peak that corresponded to the peak seen when synthetic PCS was added to normal plasma. 
When uremic plasma was treated with sulfatase, this peak disappeared and new peak appeared which 
could be quantitatively accounted for by the deconjugation of PCS to p-cresol. 
The finding that uremic plasma contains no detectable p-cresol is at variance with the results of 
many previous reports (4,8,13– 17,21). We believe this is because acid has been used to deproteinize 
plasma in these studies. Our results are in accord, however, with those of Wengle and Hellstro¨m
(26,27), who first employed gas chromatography/mass spectroscopy to assay serum phenols. They 
reported that p-cresol does not circulate unconjugated but can be released by acid hydrolysis of a 
conjugate, which they presumed to be the sulfate. Variable hydrolysis of PCS during acid deproteination 
presumably accounts for some of the wide variability in p-cresol levels subsequently reported in dialysis 
patients. We found that a higher portion of PCS is recovered as p-cresol when deproteination is 
performed with sulfuric acid as described by Bammens et al. (21) than when deproteination is performed 
with hydrochloric acid as described by De Smet et al. (20). Consistent with this difference, the former 
group of investigators has reported higher average p-cresol levels in dialysis patients than the latter (14– 
17,21). 
The finding that p-cresol sulfate and not p-cresol accumulates in uremia is not surprising in light of
our knowledge of the metabolism of other aromatic waste products. P-cresol is presumably converted to 
PCS in the liver, which performs numerous sulfation reactions (28,29). Indican, for example, is pro­
duced by hepatic oxidation and sulfation of indole, which, like p-cresol, is made by gut bacteria. 
Sulfation generally increases the solubility and often increases the albumin binding of organic 
compounds. Sulfation may also decrease toxicity. In this regard, Vanholder et al. (12) have found that 
the respiratory burst activity of phagocytes is inhibited by p-cresol but not by PCS. It may be necessary 
to re-evaluate other reported in vitro toxicities of p-cresol in light of the current findings. The conclusion 
  
 
 
 
 
 
that p-cresol measured in uremic plasma has derived from PCS would not, however, lessen the 
significance of the association of p-cresol levels with morbidity in dialysis patients (16,21). 
Our results do not prove that PCS is the only form in which p-cresol circulates. Evidence has 
recently been presented that p-cresol infused into rats is excreted partly in the form of the glucuronide 
(30). Niwa et al. (31) found that indoxyl sulfate and indoxyl-glucuronide are both present in the serum
of uremic humans, but that the sulfate greatly predominates. Niwa et al. (8) further detected p-cresol in 
ultrafiltrates of uremic plasma treated with glucuronidase, but in this study glucuronidase treatment was 
followed by acidification to pH 1 which may have hydrolyzed PCS. We could not detect p-cresol in 
uremic plasma which was incubated with glucuronidase without acid treatment (unpublished 
observations). Because we were not able to synthesize p-cresol–glucuronide, however, we could not test
the recovery of p-cresol using this procedure, and our results must be regarded as inconclusive. 
Having established that uremic plasma contains PCS and not p-cresol, we evaluated the removal of 
PCS during hemodialysis and compared it to the removal of indican. Our goal was to determine if we 
could account for the clearance of PCS in vivo based on its measured binding to plasma proteins. We
found that our model for the clearance of protein-bound solutes predicted the relation of PCS and 
indican clearances to urea clearance with reasonable accuracy, but overestimated the clearance of each 
solute. We suspect that the model overestimates clearance largely because of errors in the input values 
for KoA. Previous studies have shown that KoA values in vivo may be 20% lower than values obtained in 
vitro during dialysis of saline solutions (32,33). Reduction of our in vitro KoA values by 20% would 
bring the predicted values for the clearance of urea, indican, and PCS to 280 ± 10, 27 ± 7, and 26 ± 3 
ml/min, respectively. Other factors could also contribute to the difference between observed and 
predicted clearance values. Of note, the observed clearances of the protein-bound solutes were greater 
than the values for Qp multiplied by the solute free fractions. This means that solutes must dissociate 
from protein as blood passes through the artificial kidney. In modeling the clearance of protein-bound 
solutes, we have assumed that their binding to protein is rapidly reversible. Slower dissociation from
protein would lower solute clearances below predicted values. In general, dissociation rates for bound 
solutes are fast in relation to the transit time of blood through artificial kidneys (34,35), but dissociation 
rates for PCS and indican have not been measured. Lastly, it should be noted that predicted clearance 
rates for protein-bound solutes are very sensitive to changes in the solute free fraction f. We found that 
values for f fell during the course of hemodialysis. This presumably reflects increased avidity of protein 
binding as the levels of competing bound solutes are reduced (36). In modeling the clearance of protein-
bound solutes, we used the mean of the values for f obtained at the beginning and the end of treatment. 
Our ability to predict clearances might be improved if we profiled f more accurately.
A final aim of our study was to calculate volumes of distribution for the protein-bound solutes. We
found that PCS and indican had volumes of distribution which were several times the estimated plasma
volume. The high ratios of distribution volume to clearance account for the limited removal of these 
solutes during hemodialysis. Protein-bound solutes restricted to the plasma space would be much more 
effectively removed. For example, if PCS had a 3-L distribution volume and a clearance of 20 ml/min, 
its plasma level would fall by approximately 75% during a 3.5-h hemodialysis treatment. Instead, we 
observed that routine hemodialysis reduced PCS and indican levels by only 20 to 30%. Our results for 
  
 
 
 
 
 
 
 
 
 
  
 
 
indican are similar to the original findings of Niwa et al. (6) and Lesaffer et al. (17). 
An unanswered question is where solutes like PCS and indican are distributed outside the plasma. In 
normal humans, about 60% of the albumin in the body is located outside the vasculature, so that a 
substance which bound exclusively to albumin would have a distribution volume of about two and a half 
times the plasma volume (37). It seems unlikely that the fraction of albumin outside the vasculature is 
increased enough in dialysis patients to account for the distribution volumes we obtained for PCS and 
indican. Of note, distribution volumes for other solutes that bind extensively to albumin, such as furo­
semide, have often been found to exceed the estimated albumin space in normal subjects (38). We
calculated volumes of distribution based on the assumption of a single compartment because we 
observed no rebound at 30 min posttreatment. Measurements over a longer interval after dialysis might 
reveal the existence of an additional, slowly equilibrating compartment. 
An obvious question is how the removal of protein-bound solutes can be increased. Fagugli et al.
(15) tested the effect of dividing the total weekly dialysis time into six rather than three sessions. They 
found that increasing treatment frequency only slightly reduced the predialysis levels of indican and p­
cresol, which is consistent with the predicted behavior of solutes for which the ratio of distribution 
volume to clearance is high. Our model predicts that the removal of protein-bound solutes can also be 
increased by raising Qd and KoA above conventional levels (23). The increase in solute removal may be 
limited, however, by a decline in solute free fractions, as bound solutes are removed during aggressive 
treatment. Theoretically, the clearance of protein-bound solutes could also be increased by chemical 
treatment to increase the solute free fraction while blood flows through the dialyzer or by various 
sorbent techniques (39,40). Further evidence that protein-bound solutes contribute to uremic toxicity 
would presumably stimulate efforts to apply such methods in practice. 
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